Group One Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-66,400
| Closed | -$202K | – | 8583 |
|
|
2024
Q4 | $202K | Buy |
66,400
+27,800
| +72% | +$121K | ﹤0.01% | 3930 |
|
|
2024
Q3 | $200K | Sell |
38,600
-12,500
| -24% | -$62.1K | ﹤0.01% | 3609 |
|
|
2024
Q2 | $131K | Sell |
51,100
-7,200
| -12% | -$24.6K | ﹤0.01% | 3736 |
|
|
2024
Q1 | $287K | Sell |
58,300
-150,200
| -72% | -$889K | ﹤0.01% | 3248 |
|
|
2023
Q4 | $1.83M | Sell |
208,500
-125,900
| -38% | -$1.03M | ﹤0.01% | 1946 |
|
|
2023
Q3 | $3.84M | Buy |
334,400
+47,700
| +17% | +$917K | 0.01% | 1107 |
|
|
2023
Q2 | $7.26M | Buy |
286,700
+40,000
| +16% | +$1.25M | 0.02% | 707 |
|
|
2023
Q1 | $7.95M | Buy |
246,700
+62,200
| +34% | +$1.94M | 0.03% | 603 |
|
|
2022
Q4 | $3.41M | Buy |
184,500
+92,700
| +101% | +$2.12M | 0.01% | 1407 |
|
|
2022
Q3 | $2.48M | Sell |
91,800
-23,700
| -21% | -$481K | ﹤0.01% | 1726 |
|
|
2022
Q2 | $1.6M | Buy |
115,500
+101,300
| +713% | +$1.56M | ﹤0.01% | 2263 |
|
|
2022
Q1 | $277K | Buy |
+14,200
| New | +$215K | ﹤0.01% | 4452 |
|
|
2021
Q4 | – | Sell |
-400
| Closed | -$11K | – | 8968 |
|
|
2021
Q3 | $11K | Hold |
400
| – | – | ﹤0.01% | 7473 |
|
|
2021
Q2 | $12K | Sell |
400
-3,100
| -89% | -$89.4K | ﹤0.01% | 7466 |
|
|
2021
Q1 | $98K | Buy |
+3,500
| New | +$96.8K | ﹤0.01% | 5686 |
|
|
2020
Q3 | – | Sell |
-7,200
| Closed | -$176K | – | 6626 |
|
|
2020
Q2 | $176K | Sell |
7,200
-200
| -3% | -$3.95K | ﹤0.01% | 3493 |
|
|
2020
Q1 | $110K | Buy |
+7,400
| New | +$153K | ﹤0.01% | 3228 |
|
|
2018
Q4 | – | Sell |
-900
| Closed | -$22K | – | 5519 |
|
|
2018
Q3 | $22K | Sell |
900
-200
| -18% | -$5.44K | ﹤0.01% | 4363 |
|
|
2018
Q2 | $30K | Buy |
1,100
+900
| +450% | +$27.1K | ﹤0.01% | 4214 |
|
|
2018
Q1 | $6K | Sell |
200
-17,300
| -99% | -$557K | ﹤0.01% | 4482 |
|
|
2017
Q4 | $626K | Buy |
+17,500
| New | +$503K | ﹤0.01% | 2076 |
|
|
2016
Q4 | – | Sell |
-500
| Closed | -$8K | – | 4909 |
|
|
2016
Q3 | $8K | Sell |
500
-1,700
| -77% | -$24.7K | ﹤0.01% | 4116 |
|
|
2016
Q2 | $30K | Sell |
2,200
-4,000
| -65% | -$70.7K | ﹤0.01% | 3608 |
|
|
2016
Q1 | $108K | Buy |
6,200
+800
| +15% | +$16.3K | ﹤0.01% | 2774 |
|
|
2015
Q4 | $184K | Buy |
+5,400
| New | +$187K | ﹤0.01% | 2551 |
|
|
2015
Q2 | – | Sell |
-200
| Closed | -$4K | – | 5237 |
|
|
2015
Q1 | $4K | Sell |
200
-2,500
| -93% | -$43.2K | ﹤0.01% | 4437 |
|
|
2014
Q4 | $46K | Buy |
+2,700
| New | +$47.2K | ﹤0.01% | 3425 |
|
Other funds holding RVNC
Group One Trading's RVNC Position: Q1 2025 in Review
Group One Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 92,379 shares — an estimated $281K sold.
Group One Trading first reported a position in RVNC in Q1 2015 and held it in 28 quarters. The position peaked at $2.22M in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Group One Trading reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Group One Trading sold 92,379 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $281K.
- Group One Trading first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 28 quarters.
- Group One Trading's Revance Therapeutics, Inc. position peaked at $2.22M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.